Tag Archives: SeraCare Life Sciences

February 2020—SeraCare Life Sciences launched genomic DNA and formalin-fixed, paraffin-embedded reference materials for tumor mutational burden measurement by next-generation sequencing assays. SeraCare collaborated with Friends of Cancer Research and International Quality Network for Pathology in the development and evaluation of a range of gDNA and FFPE-based TMB reference materials across different targeted NGS panels, sequencing platforms, and bioinformatics analysis pipelines.

January 2019—SeraCare Life Sciences announced an exclusive partnership with AccuRef Diagnostics, a division of Applied StemCell, to market and sell AccuRef’s portfolio of CRISPR-engineered cell line reference materials alongside the Seraseq portfolio of NGS cancer products.

August 2017—SeraCare Life Sciences launched iQ NGS QC Management v2, data management software that supports whole-workflow data capture from sample preparation to variant calling along with associated reagent and operator data. The software enables laboratories to re-create their QC workflows, set up their critical quality control metrics in the software, and have the data imported automatically using the new iQ Connector API—all to provide real-time insights into performance.

July 2017—SeraCare Life Sciences launched the industry’s first multiplexed inherited cancer reference material for inherited disease testing by next-generation sequencing, according to the company. The Seraseq Inherited Cancer DNA Mix reference materials were developed to validate the ability of synthetic reference materials to address technically challenging variants.

April 2017—SeraCare Life Sciences launched its Seraseq Fusion RNA Mix v2 and Seraseq FFPE Fusion RNA Reference Material v2. The highly multiplexed mixes include 15 clinically actionable fusion RNA partners. Two formats are offered—purified nucleic acid (Fusion RNA Mix) and formalin-fixed, paraffin-embedded tissue slices (FFPE Fusion RNA Reference material).

August 2016—SeraCare Life Sciences and the U.S. Department of Commerce National Institute of Standards and Technology have signed a three-year cooperative research and development agreement (CRADA) to advance the development of circulating tumor DNA diagnostic assay reference standard materials.

June 2016—SeraCare Life Sciences launched its AccuPlex Zika Reference Material aimed to provide a safe, nonreplicative, and fully extractable positive material that covers the entire Zika virus genome.

June 2016—SeraCare Life Sciences launched an expanded product line to support NGS-based somatic tumor profiling assay development, validation, and QC performance monitoring. The eight new Seraseq Solid Tumor Mutation Mix-II products contain 40 somatic variants with increases in the number of insertion-deletion mutations from four to 13 to challenge both the sequencing and variant calling algorithms.

April 2016—Swift Biosciences and SeraCare Life Sciences will partner to accelerate development of a novel circulating tumor DNA reference material.

SeraCare Life Sciences’ new precision medicine business unit has launched its first product, the Seraseq Solid Tumor Mutation Mix—I (AF20), a biosynthetic reference material designed to evaluate the performance of next-generation-sequencing–based tumor profiling assays.

October 2014—SeraCare Life Sciences announced the launch of its Accurun 501 C. difficile Control, the company’s first molecular control product targeting hospital-acquired infections.

August 2014—SeraCare Life Sciences released four research panels that deliver hard-to-find material for hepatitis C, Chagas, and dengue.

June 2014—SeraCare launched its Accurun 611 product, a reference material that provides heterozygous, mutant, or wild-type scores for Factor II, Factor V, and Methlyenetetrahydrofolate reductase.

April 2014—SeraCare Life Sciences is offering a nine-member panel made from serial dilutions of a cultured virus with established reactivity for CMV DNA called the CMV DNA AccuSpan Linearity Panel.

SeraCare Life Sciences has acquired Kirkegaard & Perry Laboratories (KPL), a provider of antibodies and related reagents for the diagnostic and life sciences markets.

SeraCare Life Sciences has introduced a new AccuSet anti-Toxoplasma performance panel.

SeraCare Life Sciences completed its implementation of SAP enterprise resource planning (ERP) software. The SAP system integrates the company’s inventory planning and control, purchasing, production management, quality management, and financial reporting systems into a single software solution.

SeraCare Life Sciences offers three new Accuvert seroconversion panels and one new Accuset performance panel. The new Accuvert seroconversion panels are HCV seroconversion panel PHV924, providing undiluted plasma samples from a single male donor of genotype 2b, drawn over an 88-day period in 2008; HCV seroconversion panel PHV925, providing undiluted plasma samples from a single male donor of genotype 1a, drawn over a 27-day period in 2008; and HCV seroconversion panel PHV926, providing undiluted plasma samples from a single male donor of genotype 3a, drawn over a 14-day period in 2009.

SeraCare Life Sciences has launched three seroconversion panels that provide difficult-to-find patient samples for hepatitis B and HIV. HBV seroconversion panel PHM938 comprises six undiluted plasma samples from a single donor drawn over a six-day period and is HBV DNA-positive from the first bleed.